RUNX1 and acute myeloid leukemia: Compared to RUNX1 wildtype (wt) (n = 470), patients with RUNX1-mutated de novo AML (n = 18) were significantly older at diagnosis (11.7 [2–17] vs. 8.3 [0–18] years, p = 0.02), (Table 1).